Highlights

• Remote pregnancy monitoring platform addressing maternal healthcare with hospital-grade monitoring at home

• FY26 reporting provides latest operational and financial update on commercialisation progress

• Commercialisation, customer adoption and platform Revenue generation are the next meaningful milestones

• Operating in a structurally growing digital maternal health market with clinical validation requirements

HeraMED Limited (ASX:HMD) is an ASX-listed digital health company that has developed the HeraMED system — a remote pregnancy monitoring platform that enables expectant mothers to measure fetal heart rate, uterine contractions, maternal heart rate and blood oxygen saturation from home, streaming the data to clinical care teams for review. The technology addresses one of the most significant challenges in obstetric care: providing clinical-grade monitoring to the growing population of pregnant women who prefer or need to manage their pregnancy care outside of hospital environments.

Latest Developments

HeraMED's latest reporting provides an update on its financial and operational position as it continues developing technology aimed at improving maternal healthcare monitoring. Recent ASX activity has largely involved securities-related matters and reporting. The company's next meaningful catalysts are likely to centre on commercialisation, customer adoption and the ability of its technology platform to generate sustainable recurring revenue.

Understanding the Business

HeraMED's platform comprises a wearable monitoring device that expectant mothers use at home and a cloud-based platform that transmits and stores the monitoring data for review by obstetricians, midwives and healthcare teams. The system is designed to meet clinical standards for fetal and maternal monitoring, enabling it to be integrated into formal antenatal care pathways rather than used only as a consumer wellness device. Clinical evidence supporting the platform's diagnostic accuracy has been published in peer-reviewed journals, providing the validation that is typically required for healthcare system adoption.

Industry Opportunity

Remote patient monitoring is one of the fastest-growing segments in digital health, accelerated by the COVID-19 pandemic's disruption to in-person clinical care and the subsequent recognition that many routine monitoring tasks can be delivered remotely without compromising clinical quality. Maternal health monitoring is a specific sub-segment with compelling Demand drivers: higher-risk pregnancies are increasing in frequency as birth rates in older age groups rise, obstetric workforce shortages are creating pressure to manage more monitoring remotely, and patients increasingly prefer monitoring solutions that reduce the burden of repeated hospital visits during pregnancy.

Key Risks

• HeraMED is pre-scale — ASX activity predominantly involves securities matters, suggesting the Business is still in early commercialisation

• Healthcare system procurement and clinical pathway integration is a slow, complex process for novel monitoring technologies

• Private health insurer reimbursement for remote pregnancy monitoring is not yet established in most markets

• Competition from other remote fetal monitoring devices and telemedicine platforms targeting the maternity care market

• Cash position requires careful management while waiting for commercial scale to be achieved

Key Catalysts to Watch

• First major hospital or health system Partnership integrating HeraMED into a formal antenatal care pathway

• Health Insurance reimbursement approval for HeraMED monitoring in Australia, Israel or another key market

• Clinical evidence publication supporting HeraMED's diagnostic equivalence to in-hospital monitoring

• International market entry beyond the company's existing footprint, opening new addressable patient populations

• Full-year FY26 results showing meaningful subscription or usage revenue growth from the monitoring platform

Conclusion

HeraMED (ASX:HMD) has developed a clinically credible remote pregnancy monitoring solution for a market — maternal health — with compelling structural demand drivers. The challenge is the long and complex process of achieving clinical pathway integration and reimbursement approval that transforms a validated technology into a commercially scaling business. The company's next meaningful catalysts are healthcare system partnerships and reimbursement approvals that would trigger meaningful platform adoption. Until those milestones are achieved, HeraMED remains a clinical-stage digital health Investment with the risks and potential upside that characterise that category.